MORGAN STANLEY PLC/PUT/NOVO NORDISK ADR B/100/0.1/19.12.25 Stock

Warrant

DE000ME1Z0Z8

Market Closed - Börse Stuttgart 15:17:57 2024-07-05 EDT
0.46 EUR 0.00% Intraday chart for MORGAN STANLEY PLC/PUT/NOVO NORDISK ADR B/100/0.1/19.12.25
3 months-45.24%
6 months-66.42%
Date Price Change
24-07-05 0.46 0.00%
24-07-04 0.46 -8.00%
24-07-03 0.5 +6.38%
24-07-02 0.47 +6.82%
24-07-01 0.44 -4.35%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 03:17 pm

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME1Z0Z
ISINDE000ME1Z0Z8
Date issued 2023-10-12
Strike 100 $
Maturity 2025-12-19 (532 Days)
Parity 10 : 1
Emission price 1.78
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.04
Lowest since issue 0.41
Delta-0.13x
Omega 3.636
Premium33.34x
Gearing28.26x
Moneyness 0.7020
Difference Strike -42.37 $
Difference Strike %-42.37%
Spread 0.01
Spread %2.13%
Theoretical value 0.4651
Implied Volatility 36.94 %
Total Loss Probability 76.00 %
Intrinsic value 0.000000
Present value 0.4650
Break even 94.96 €
Theta-0.01x
Vega0.03x
Rho-0.02x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974 DKK
Average target price
952.2 DKK
Spread / Average Target
-2.24%
Consensus